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Abstract It is well established that lead (Pb) exposure in
humans leads to learning and memory impairment. How-
ever, the biological and molecular mechanisms are still not
clearly understood. When over activated, serine/threonine
protein phosphatases are known to function as a constraint
on learning and memory. Activation of these phosphatases
can also result in cytoskeletal changes that will adversely
affect learning and memory. We investigated the effects of
Pb exposure on these phosphatases in primary cultures of
human neurons. Neurons were exposed to physiologically
relevant concentrations of Pb (5, 10, 20 and 40 lg/dL)
and total phosphatase and PP2A activities were determined
in neuronal lysate using para-nitrophenyl phosphate
(pNPP), and a PP2A-speciﬁc phosphopeptide as substrates.
Expression of various serine/threonine phosphatases, tau
and its phosphorylation state were determined by Western
blot (WB) and immunocytochemistry (ICC). We found that
the total phosphatase activity in the neuronal lysate was
increased by 30–50% by all the concentrations of Pb tested.
PP2A activity was increased by 5 lg/dL Pb only. PP1
expression was increased (ranging from 25–50%) by 10, 20
and 40 lg/dL of Pb. PP2B expression was increased sub-
stantially (up to 2.5-fold) by 10 lg/dL Pb, whereas, higher
concentrations did not show any effect. On the other hand,
Pb (at all concentrations used) decreased expression of
PP2A and PP5. Pb exposure induced substantial hyper-
phosphorylation of tau at serine 199/202 by 5 and 10 lg/dL
Pb, and Threonine 231 at higher doses. Expression of total
tau was mostly unaffected by lead. Immunocytochemistry
data conﬁrmed the WB results of expression of PP1, PP2A,
tau protein and the phosphorylation of tau. These results
support our hypothesis that Pb exposure up regulates some
of the serine/threonine phosphatases (PP1 and PP2B) that
are known to impair memory formation, and suggest a
novel mechanism of Pb neurotoxicity.
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Introduction
Lead (Pb) is a toxic heavy metal that can affect several
organs including the nervous, hematopoietic, renal, repro-
ductive, endocrine and skeletal systems [1, 2]. The central
nervous system (CNS) is particularly sensitive to Pb tox-
icity and is affected even by low doses [3, 4]. Lead
exposure is associated with growth retardation in children
[5, 6]. Exposure to low levels of Pb (as low as 7 lg/dL) is
associated with impairment of cognitive and behavioural
development in children [7, 8] and in young adults [9].
There is strong evidence that low-dose Pb exposure is
causally associated with deﬁcits in cognition [10]. An
estimated decrease of 4–7 points in the mean IQ score for
each 10 lg/dL increase in blood Pb has been reported [10].
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DOI 10.1007/s11064-010-0300-6Pb preferentially distributes in speciﬁc areas of the brain
with the highest levels observed in the hippocampus and
cerebral cortex—areas that are associated with learning and
memory [11]. The exact mechanism(s) by which lead get
into the body, and particularly into the brain, is still
unknown as no Pb speciﬁc transporter(s) has been identi-
ﬁed. However, it has been postulated that Pb might use the
divalent metal ion transporter 1 (DMT1), which is used by
several essential elements [12]. DMT1 is localized in
astrocytes and neurons in the normal brain [13–15]. The
developing brain is a primary target for lead-induced
neurotoxicity. However, the mechanism of lead-induced
neurotoxicity and deﬁcits in learning and memory is not
well understood. Neurogenesis and synaptogenesis are the
main components of learning and memory and these are
both known to be affected by Pb [16–19].
Protein phosphorylation/dephosphorylation is one of the
key events in the regulation of several cellular events
including synaptogenesis. Reversible protein phosphoryla-
tion is the result of a delicate coordinated balance between
protein kinases and protein phosphatases. The major serine/
threonine protein phosphatases in the brain are PP1, PP2A
and PP2B [20, 21]. These phosphatases, together with
protein kinases, contribute to the control of synaptic plas-
ticity and memory [22–27]. In the last decade, researchers
have clearly demonstrated the importance of protein
kinases in short and long-term modiﬁcation of signal
transmission between synapses. However, the roles of
protein phosphatases have been appreciated recently and
need to be further investigated.
Over-expression/over-activation of some of serine/thre-
onine protein phosphatases has been associated with sup-
pression of learning and memory. The role of PP1 in
learning and memory has been widely studied [28, 29].
Inhibition of PP1 activity, either genetically or pharmaco-
logically, enhanced learning capacity, suggesting that PP1
is a constraint on memory. This enhancement in learning
was correlated with increased phosphorylation of several
synaptic and nuclear targets of PP1 including GluR1,
CaMKII, and CREB proteins. After learning, inhibition of
PP1 prolonged memory, suggesting that PP1 also promotes
forgetting. Thus PP1 appears to be a suppressor of learning
and memory [30–33]. It has been suggested that PP1
determines the efﬁcacy of learning and memory by limiting
acquisition of information and favouring memory decline.
When PP1 is inhibited, short intervals between training
episodes are sufﬁcient for optimal performance [31]. In
addition to PP1, PP2A and PP2B are also known to
adversely affect learning and memory [23, 32, 34, 35].
Mice over-expressing calcineurin (PP2B) have normal
short-term memory but have profound and speciﬁc defect
in long-term (hippocampal dependent) memory. The spe-
ciﬁc defects in long-term memory may be due to a defect in
transition between short-term and long-term memory [23].
The effect of Pb exposure on the activity or expression of
these phosphatases thus far has not been investigated in
humans or in animal models.
An intact microtubule structure is essential for normal
neuronal functioning. Disruption of microtubules has been
shown to be associated with memory loss and neuronal
death [36]. The microtubule network is stabilized by sev-
eral microtubule-associated proteins (MAP); tau is one of
them. Tau can be phosphorylated at several serine or
threonine residues [37]. Phosphorylation of tau at a stoi-
cheometry of 2–3 mol phosphates per mole of protein is
required for promoting assembly and stability of the
microtubule, whereas, its hyperphosphorylation (9–10 mol
of phosphate per mole of tau) results in the disruption and
disassembly of microtubule and subsequently in memory
loss and neuronal death [38–41]. As the phosphorylation
state of tau is regulated by the balance between protein
kinases and protein phosphatises, over-expression and/or
over-activation of phosphatases (PP1, PP2A or PP2B) will
affect phosphorylation level of tau and thus the stability of
microtubule.
In this study, we tested the hypotheses that exposure of
human neurons to Pb results in over-expression or over-
activation of serine/threonine protein phosphatases. The
results presented here support this hypothesis and suggest a
novel mechanism of lead-induced impairment of learning
and memory, as these phosphatases are known to directly
impair learning and memory.
Materials and Methods
Reagents and Chemicals
All neuronal cell culture media and additives were from
Invitrogen (Mulgrave, VIC, Australia) unless otherwise
stated. All chemical used for Western blot, immunopre-
cipitation, PPase activity and immunoblot (unless men-
tioned) were obtained from Sigma-Aldrich Chemical Co.
(Sydney, NSW, Australia). The list of primary antibodies
and their sources is given in Table 1. Prof Alistair Sim
(University of Newcastle, NSW, Australia) kindly provided
the PP1 antibody (PP1c). Secondary anti-mouse and anti-
rabbit IgG and anti-rabbit Alexa 594 (Red)-conjugated
antibodies were purchased from Molecular probes
(Eugene, OR, USA). All commercial antibodies were used
at the concentrations recommended by the manufacturer.
Cell Cultures
Human foetal brains were obtained from 16 to 19 week old
foetuses collected following therapeutic termination with
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123informed consent (Ethic approval HREC03187). Primary
cultures of human neurons were prepared as described
previously [42]. Brieﬂy, cells were plated in 12-well tissue
culture plates coated with Matrigel (diluted 1/20 in Neu-
robasal medium) and maintained in Neurobasal medium
supplemented with 2% (v/v) B-27 supplement, 2 mM
Glutamax, 50 mM HEPES, 200 IU/mL penicillin G, and
200 lg/mL streptomycin sulphate and 5 mM glucose.
Cultures were kept at 37Ca t5 %C O 2 in a humidiﬁed
atmosphere. The medium was changed once to twice per
week. We used 3 week-old highly pure neuronal cultures
for the experiments.
Preparation of Neuronal Lysate for Western Blots
For Western Blots, cells were cultured in Matrigel coated
12-well plates at a density of 1 9 10
6 cells per well in
supplemented Neurobasal medium (as described above).
Neurons were cultured with 5, 10, 20 and 40 lg/dL of
elemental Pb for 72 h. A 10 lg/mL Pb solution was pre-
pared by dissolving 183.07 mg of Pb(II) acetate trihydrate
(Pb(C2H3O2)23H2O; FW 379.33) in 10 mL of deionised
and sterilized water, taking into account the MW of lead as
207.20. Control cultures were kept in the medium alone.
Cells were lysed in 500 lL of RIFA buffer (50 mM Tris,
pH 7.4, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5%
sod. deoxycholate, 0.1% SDS, 50 nM NaF, 1 mM sodium
vanadate, and protease inhibitor cocktail (Roche Diagnos-
tic, Castle Hill, NSW, Australia). The cell lysate was
centrifuged at 16,000g for 10 min. Protein concentration in
the supernatant was determined by the Bradford method
(Sigma) and stored at -20C until used.
SDS–PAGE and Immunoblot Analyses
20 lg lysate protein was resolved on 10% SDS–PAGE
(NuPAGE 10% from Invitrogen, Carlsbad CA USA) in
sample buffer. Protein was transferred onto PVDF mem-
branes; the membranes were blocked with 5% milk in TBS
for 1 h and incubated with primary antibody overnight at
4C. The primary antibodies used are described in Table 1.
After incubation, the membranes were rinsed several times,
washed with TBS-tween three times (10 min each), and
then two times with TBS only. The membranes were then
incubated with the secondary antibody for 4 h at RT,
washed as before and developed with ECL (Biorad,
Gladesville, NSW, Australia) according to the manufac-
turer instructions. Blots were scanned and quantiﬁed using
the software ImageJ from NIH (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, MD, USA,
http://rsb.info.nih.gov/ij/, 1997–2007).
Phosphatase Activity Assay
For phosphatase activity, cells were cultured as described
above and lysed in the phosphatase activity buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM PMSF,
1 mM Benzamidine, 10 mM beta-mercaptoethanol (bME),
and protease inhibitor cocktail. Total phosphatase activity
was determined using pNPP (10 mM) as a substrate in
50 mM Tris–HCl, pH 7.4, 0.1 mg/mL BSA, 3 mM CaCl2,
1 lM calmodulin and 3 mM MnCl2. The reaction mixture
was incubated at 30C for 30 min and the absorbance
measured at 405 nm. PP2A activity was indirectly mea-
sured by using 10 nM okadaic acid (OA) in the phospha-
tase assay buffer and then calculating the OA-inhibited
activity.
Direct Estimation of PP2A Activity
Cells were cultured with various concentrations of Pb for
24 h.Cellswereharvestedandthelysatepreparedin20 mM
imidazole–HCl, pH 7.0, 2 mM EDTA, 2 mM EGTA, and
the protease inhibitor cocktail. PP2A activity was measured
with the PP2A immunoprecipitation phosphatase assay kit
(Cat. # 17-313; Millipore, Temecula, CA, USA) according
the manufacturer protocol. Brieﬂy, 200 lg neuronal lysate
protein was immunoprecipitated with anti-PP2A (clone
Table 1 List of primary antibodies used in this study
Antibody Type Isotype Antigen Dilution Source/reference
Tau pAb – Total tau 1:2,000 DakoCytomation, Denmark
PHF-TAU, (clone AT8) mAb IgG1 k pS199/202 1:100 Innogenetics, Ghent, Belgium
PHF-TAU, (clone AT180) mAb IgG1 k pT231 1:100 Innogenetics, Ghent, Belgium
Anti-PP2B pAb – Catalytic subunit B 1:200 Upstate, Lake Placid, NY, USA
Anti-PP5 pAb – PP5 1:200 Sigma-Aldrich, Castle Hill, Australia
Anti-b-actin (clone AC-15) mAb IgG1 b-Actin 1:2,000 Sigma-Aldrich, Castle Hill, Australia
Anti-PP1 pAb – PP1c 1:1,000 Donated by Prof Alistair Sim
Anti-PP2A (clone 1D6) mAb IgG2bj PP2Ac 1:5,000 Upstate, Lake Placid, NY, USA
pAb polyclonal, mAb monoclonal
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1231D6) and the activity of the immunoprecipitated PP2A was
estimated by colorimetrically measuring the released phos-
phate from threonine phosphopeptide (K-R-pT-I-R-R) with
Malachite Green phosphate detection solution.
Immunocytochemistry
The method was previously described [38]. Human foetal
neurons were grown at the density 5 9 10
6 in Permanox
chamber-slides (NUNC) for 2 weeks. Then, cells were ﬁxed
with acetone/methanol (vol/vol) for 20 min at -20C. Cells
were then rinsed three times with PBS and a gentle mem-
branouspermeabilizationwas performed byincubationwith
0.025% Triton x100inPBSfor10 minatroom temperature.
After washing, cells were incubated with 5% normal goat
serum (NGS) in PBS for45 min at room temperature, rinsed
twice with PBS and incubated for 1 h at 37C with selected
primary antibodies diluted in 5% NGS. Antibodies used are
Tau (for total tau), AT8 and AT-180, anti-PP1, anti-PP2A
(clone 1D6). Cells were then washed with 5% NGS solution
and incubated for 1 h at 37C with the appropriate labelled
secondary antibodies (Goat anti-mouse IgG or goat
anti-rabbit coupled with Alexa 594). Nuclear staining was
performed using DAPI at 1 lg/mL for 5 min at room tem-
perature.AfterseveralwashingswithPBSat37C,thecover
slips were quickly mounted on glass slides with Fluoro-
mount-G, and were examined with an Olympus BX60
ﬂuorescence microscope associated with a digital Sensi-
Cam. The following three controls were performed for each
labelling experiment: (1) isotypic antibody controls for
mAbs and serum control for pAbs, (2) incubation with only
the secondary labelled antibodies, (3) estimation of auto-
ﬂuorescence of unlabelled cells. Fluorescence intensity was
quantiﬁed using ImageJ 1.38 for Mac OSX (NIH, USA).
Statistical Analyses
Each experiment was repeated at least three times, unless
otherwise stated. The number of replicates for each
experiment is shown in the ﬁgure legends. Student t test of
two independent samples with unequal variances was used
to measure the signiﬁcance level of the difference between
control and various levels of Pb treatments. Signiﬁcance
level was set at P\0.05.
Results
Lead Exposure Increases Phosphatase Activity
in Human Neurons
To investigate the effect of Pb exposure on phosphatase
activity in cultured primary human neurons, we cultured
neurons with increasing concentrations of Pb for 72 h and
measured phosphatase activity using pNPP as substrate.
The results are shown in Fig. 1. All concentrations of Pb
tested induced a signiﬁcant increase (P\0.05) in total
phosphatase activity. The increase in phosphatise activity
ranged from 30–46% compared to control levels but was
not dose dependent (Fig. 1a). The PP2A activity, which
was indirectly calculated as okadaic acid (10 nM)—
inhibited activity, was substantially and signiﬁcantly (P B
0.01) increased (50%) with 5 lg/dL lead. Higher concen-
trations of Pb (10, 20 and 40 lg/dL) slightly decreased
PP2A activity, but the decrease was not statistically sig-
niﬁcant (Fig. 1b). Direct measurement of PP2A activity
with a PP2A activity assay kit, which involves the release
of phosphate from threonine phosphopeptide (K-R-pT-I-R-
R) by the immunoprecipitated PP2A, revealed similar
results. In this case 5 lg/dL Pb signiﬁcantly (P\0.05)
increased PP2A activity, whereas, higher concentrations of
Pb did not signiﬁcantly affect PP2A activity.
Lead exposure Dysregulates the Expression of Serine/
Threonine Protein Phosphatases
We investigated the levels of protein expression of several
serine/threonine protein phosphatases in the lysate of
Pb-treated neurons. The results of these experiments are
shown in Fig. 2. Pb at 10, 20 40 lg/dL signiﬁcantly
increased PP1 expression (P\0.05); the highest increase
(51%) was observed in neurons treated with 10 lg/dL Pb
(Fig. 2a). Similarly, a 1.8 and 2.5-fold increase in PP2B
expression was seen, respectively, in neurons treated with 5
and 10 lg/dL Pb, however, only the effect of 10 lg/dL Pb
was statistically signiﬁcant (P\0.02). Higher concentra-
tions did not show any effect on PP2B expression (Fig. 2b).
Expression of PP2A was signiﬁcantly (P\0.01) decreased
by all concentrations of Pb tested (Fig. 2c). PP5 expression
was also decreased by Pb in a dose-dependent manner.
Fig. 1 Lead affects protein phosphatase activities in cultured human
neurons. a Neurons were cultured with various levels of Pb for 72 h.
Cells were lysed in the phosphatase activity buffer. Total phosphatase
activity was determined using pNPP (10 mM) as a substrate, as
described in Material and Methods. Phosphatase activity of cultures
treatedwithdifferentconcentrationsofPbisexpressedaspercentofthe
control cultures. Data presented are the mean ± SD of three experi-
ments. b PP2A activity was indirectly measured in the presence of 10
nMOAinthephosphataseassaybuffer.PP2Aactivitywascalculatedas
the difference between total activity and activity in presence of OA
(OA-inhibited activity). PP2A activity is the average of three exper-
iments and expressed as percent of the control cultures. c PP2A was
immunoprecipitated with anti-PP2A (clone 1D6) and the activity was
determined as described in Materials and Methods. Data presented are
the average of two separate experiments and the PP2A activity is
expressed as the picomoles of phosphate released by PP2A from the
phosphopeptide included in the kit. * signiﬁcantly different from
control (P\0.05), ** signiﬁcantly different from control (P\0.01)
c
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123Pb at 5 lg/dL decreased PP5 expression but the decrease
was statistically not signiﬁcant (P = 0.09). Higher con-
centrations of Pb signiﬁcantly decreased PP5 expression
(P\0.01). PP5 was more sensitive to Pb than PP2A. Pb at
40 lg/dL decreased PP5 expression to less than 20% of
control. The increase in PP1 expression and the decrease in
PP2A expression with Pb treatments were conﬁrmed with
immunocytochemistry (Fig. 4).
Lead Exposure Affects the Phosphorylation State
of Tau Protein
Since serine/threonine phosphatases modulate the rate of
phosphorylation of the phosphoprotein tau, and Pb affects
the activity and expression of these phosphatases, we
investigated if Pb exposure would also affect the expres-
sion and phosphorylation of tau protein. All concentrations
of Pb tested resulted in a modest increase in the expression
of tau in a non-dose-dependent manner but the increase did
not reach statistical signiﬁcance (Fig. 3a). With regards to
tau phosphorylation, Pb at 5 and 10 lg/dL resulted in
signiﬁcant increase in tau phosphorylation at the AT8 site.
Higher concentration of Pb had no appreciable effect at tau
phosphorylation at this site (Fig. 3b). At the AT-180 site,
an increase in phosphorylation was observed with all levels
of Pb tested but only the highest concentration (40 lg/dL)
resulted in statistically signiﬁcant increase in the phos-
phorylation of tau (Fig. 3c). We also tested the phosphor-
ylation of tau at these two sites (AT8 and AT-180) by
immunocytochemistry using 5 and 20 lg/dL Pb. Pb at
5 lg/dL substantially increased tau phosphorylation at AT8
and AT-180 sites, whereas, phosphorylation at these sites
was not substantially affected by 20 lg/dL Pb (Fig. 4c, d).
No signiﬁcant effect of Pb on the expression of total tau
was observed by immunocytochemistry, similar to the
Western blot results (Fig. 4a).
Discussion
We found that Pb in pathophysiological relevant concen-
trations increased total phosphatase activity and PP2A
activity in primary cultures of human neurons. Pb also
resulted in increased expression of PP1 and PP2B but it
decreased the expression of PP2A and PP5. Pb substan-
tially increased phosphorylation of serine 199/202 of tau
(AT-8 site) particularly at lower doses (5 and 10 lg/dL),
whereas, phosphorylation of threonine 231 was more pro-
nounced at higher dose (40 lg/dL). These results suggest
two possible mechanisms for Pb-induced impairment of
learning and memory. First, Pb treatment (exposure)
induces over-expression (PP1 and PP2B) and over-activa-
tion (PP2A) of serine/threonine protein phosphatases.
Over-activation of these phosphatases is associated with
learning and memory impairment [28–35]. Second, Pb
exposure results in hyperphosphorylation of tau which may
subsequently result in cytoskeletal disruption in neurons.
Such structural changes are also reported to be responsible
for memory loss in many tauopathies [38–41].
Our study is unique in three aspects. Firstly, we mea-
sured the activity and expression of PP1, PP2A and PP2B
in primary cultures of human neurons. To our knowledge,
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Pb-induced changes at the molecular level in human neu-
rons. Previous studies have been performed using animal
models; however, these results may not be fully relevant
for humans. Secondly, the effects of Pb exposure on brain
phosphatases have not been studied before in humans or in
animal models. Finally, we used pathophysiological levels
of Pb that are in accordance with the blood levels of
humans that have been exposed to environmental Pb
contamination.
We found a 30–46% increase in total phosphatase
activity in neurons treated with Pb for 72 h. Since PP2A
accounts for the majority (*70%) of the brain phosphatase
activity, we used two approaches the measure the activity
of this phosphatase. (1) Okadaic acid at 10 nM concen-
tration speciﬁcally inhibits PP2A activity without affecting
PP1 or PP2B activity [43]. We used this approach to
indirectly estimate PP2A activity. Using this method, we
found that PP2A activity was particularly sensitive to Pb
effect and we observed a signiﬁcant increase (50%) but
only with a small dose of Pb (5 lg/dL). Higher doses were
not effective and resulted only in a limited (non-signiﬁcant)
decrease in PP2A activity. (2) A commercially available kit
(Millipore, Temecula, CA, USA), which speciﬁcally mea-
sure PP2A activity was used. This technique involves the
immunoprecipitation of PP2A with the anti-PP2A antibody
(clone 1D6) and measuring the released phosphate by
PP2A colorimetrically from a phosphopeptide. The results
obtained from this approach were in perfect agreement
with the okadaic acid-inhibited activity (Fig. 1b, c). From
these results it can be conﬁdently inferred that PP2A is
more sensitive to lower doses of Pb and that such increase
in PP2A activity by low doses of Pb may responsible for
reported CNS toxicity [3, 4] and impairment of learning
and memory [10] by low doses of Pb.
Several serien/threonine protein phosphatases are
expressed in the brain. Of these, the major phosphatases in
the brain are PP1, PP2A and PP2B [20, 21], with PP2A
being the major one. PP2A (together with PP1) accounts
c Fig. 2 Lead increases the expression of PP1and PP2B but decreases
the expression PP2A and PP5. Primary foetal human neurons were
cultured in Matrigel coated 12-well plates at a density of 1 9 10
6
cells per well with various concentrations of Pb for 72 h. Control
cultures were kept in the medium alone. Cells were lysed in 500 lL
of RIFA buffer, and 20 lg lysate protein was resolved on 10% SDS–
PAGE and immunoblotted with antibodies to a PP1, b PP2A, c PP2B
and d PP5. Blots were scanned and quantiﬁed using the software
ImageJ from NIH. Anti-actin antibody was used as loading control to
which data was normalized. Data are expressed as percent of control
cultures and represent as mean ± SD of three experiment (for PP1
and PP2B) and six experiments (PP2A and PP5). Representative blots
are shown with the graphs. * signiﬁcantly different from control
(P\0.05), ** signiﬁcantly different from control (P\0.01)
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123for over 90% of the total mammalian brain protein phos-
phatase activity [44, 45]. PP2A alone also accounts for
71% of the brain tau phosphatase activity [46]. Our results
suggest that different phosphatases are affected differently
by Pb. We observed an increase in PP1 and PP2B
expression but a decrease in the expression of PP2A and
PP5. The increase in PP1 and PP2B expression may be a
mechanism to compensate for the decrease in PP2A
expression. Our results also suggest that the increase in
total phosphatase activity, particularly at Pb doses higher
than 5 lg/dL may be mainly due to an increase in PP1 and
PP2B activity. However, this could not be veriﬁed as we
did not individually determine the activities of PP1 and
PP2B.
Treatment with low-level of Pb (5 lg/dL) resulted in
increased activity of PP2A but a decrease of its expression.
The reason for this apparent discrepancy between activity
and expression of PP2A by Pb is not clear but could likely
be explained by the complex structure and regulatory
system of PP2A. PP2A is a trimeric protein consisting of a
catalytic subunit C, a scaffolding subunit A and a regula-
tory subunit B. There are two isoforms of C, two isoforms
of A and at least 18 isoforms of the regulatory subunit B.
The expression levels of the A and C subunits are uniform
throughout the brain but the expression levels of various
regulatory subunits are highly variable depending upon cell
types and tissues [47, 48]. Different combinatorial associ-
ations of the different A, B and the C subunits can generate
75 different trimeric PP2A holoenzymes. The activity of
the holoenzyme towards different substrates is greatly
modulated by the regulatory subunit B. These may mod-
ulate (1) the tissue localization and targeting the enzyme to
particular cellular compartments, (2) the substrate speci-
ﬁcity, and (3) catalytic activity toward the same substrate
in response to different agents [47]. The C subunit as such
is more active towards phosphoprotein substrates than is
the core enzyme (Subunits A and C) in vitro, whereas it is
the opposite for activity towards phosphopeptides [49, 50].
Similarly, the B subunits also modulate the catalytic
activity of the core enzyme, suppressing activity towards
some substrates, but greatly enhancing the dephosphoryl-
ation of others (reviewed by Janssens and Goris [47]).
Whether Pb affects the association of the catalytic subunit
of PP2A with other subunits or results in the selective
expression of different regulatory subunits needs to be
further investigated.
In addition to the direct impairment of learning and
memory due to increase in the activity of phosphatases, Pb
may also indirectly impair learning and memory by causing
cytoskeletal changes in neurons by modulating the
Fig. 3 Lead induces tau hyperphosphorylation in human neurons.
Neurons were treated with various concentration of Pb for 72 h as
described before. Cells were lysed in RIFA buffer and Western blot
was performed using antibodies towards a total tau (tau), b tau
phosphorylated at serine 199/202 (AT8) and c threonine 231 (AT180).
Anti-actin antibody was used as loading control to which the data for
total tau was normalized. The signal for AT8 and AT180 was
normalized to the signal for total tau and is presented as arbitrary
units. Quantitation shown is the average of two experiments from two
separate neuronal cultures. Antibody dilution is shown in Table 1.
*signiﬁcantly different from control (P\0.05), ** signiﬁcantly
different from control (P\0.01)
c
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123phosphorylation state of the tau protein. We observed a
substantial increase in tau phosphorylation at two sites
(serine 199/202 and threonine 231) in human neurons
treated with various concentrations of Pb. An increase in
the expression of phosphorylated tau in the hippocampus of
mouse pups exposed to Pb in their early life has recently
been reported [51]. Tau is a phosphoprotein that can be
phosphorylated at multiple serine and threonine residues.
Hyperphosphorylated tau is assembled into paired helical
ﬁlaments (PHF) of neuroﬁbrillary tangles [52, 53]. At least
30 serine/threonine phosphorylation sites have been iden-
tiﬁed in abnormally hyperphosphorylated tau [37]. Phos-
phorylation of tau at a stoicheometry of 2–3 mol
phosphates per mole of protein is required for promoting
assembly and stability of microtubule, whereas, its hyper-
phosphorylation (9–10 mol of phosphate per mole of tau)
results in the disruption and disassembly of microtubule
and subsequently in memory loss and neuronal death [36,
37, 41]. The disruption of microtubules in neurons by the
hyperphosphorylated tau is one of the fundamental aspects
of dementia in Alzheimer’s disease and other tauopathies
[52–57]. Whether tau phosphorylation is involved in Pb-
induced deﬁcits in learning in young children is still
unknown, and needs to be further investigated. However,
several studies have shown that phosphorylated tau, irre-
spective of NFT accumulation, is responsible for memory
deﬁcits in many models of tauopathies (other than Alz-
heimer’s disease) such as Drosophila [58], mouse [59] and
rat [60]. Based on these reports it would not be surprising if
such mechanism also affect young children exposed to
lead. The increase in tau phosphorylation at low dose of
lead (5 lg/dL), particularly at serine 199/202 may be a
mechanism for the reported impairment of learning and
memory in children. This ﬁnding is in accordance with the
published literature showing that Pb even at low doses (as
low as \7 lg/dL) causes subtle alteration in synaptogen-
esis and impairs learning and memory, whereas, at high
doses, it can cause encephalopathy [16, 61, 62].
In summary, we report here that Pb exposure, in path-
ophysiological concentrations, increases the activity and
expression of different serine/threonine protein phospha-
tases. Pb exposure also induces hyperphosphorylation of
Fig. 4 Dysregulation of protein phosphatases and tau phosphoryla-
tion by lead in human neurons. Primary foetal human neurons were
cultured in Matrigel coated 12-well plates at a density of 1 9 10
6
cells per well with 5 lg/dL and 20 lg/dL Pb for 24 h. Control
cultures were kept in the medium alone. a Cultures were immuno-
stained for total tau, tau phosphorylation with two different antibodies
(AT8 and AT180), and PP1 and PP2A expression as described in
Materials and Methods. The blue labelling with DAPI stained all cell
nuclei and the red staining Tau. b Quantitative presentation of the
immunohistochemistry staining. For each antibody used, the left
column corresponds to untreated neurons, the middle column to 5 lg/
dL Pb treated cells and the right column to 20 lg/dL Pb treated cells.
The histograms represent the semi-quantiﬁcation of the immuno-
staining intensity. Intensity has been quantiﬁed using ImageJ 1.38 for
Mac OSX (NIH, USA). Three individual microscopic ﬁelds were
analysed for each treatment and the SEM for the data was determined
to be\5%. For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the online version of this article. (mail
as on 15/7/2006)
202 Neurochem Res (2011) 36:195–204
123tau at several sites. These data suggest that Pb may impair
learning and memory by two mechanisms: (1) by up-reg-
ulating the activity (PP2A and possibly PP1 and PP2B) and
expression (PP1 and PP2B) of protein phosphatases, which
are known to impair learning and memory formation and
(2) by inducing hyperphosphorylation of tau protein and
the subsequent cytoskeletal changes in neurons.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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